TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects aged 18 to85 years who gave written informed consent.~* Subjects must have a history of chronic, symptomatic, New York Heart Association (NYHA) Class II-III CHF and impaired renal function (baseline eGFR of 20 to 75 mL/min/1.73m2).~* Congestive heart failure should have been diagnosed at least 3 months before Visit 1 (Day 1) and the subjects should be on chronic treatment with furosemide (40 mg daily) for at least 3 weeks before Visit 1 (Day 1).~* Subjects must be on stable doses of their individually optimized medication regimen for at least 4 weeks before Visit 1 (Day 1).~Exclusion Criteria:~* Any history of a convulsive disorder or pre-convulsive state and any risk for a convulsive disorder or pre-convulsive state (for example any past brain trauma, abuse of alcohol) will lead to an exclusion from the study.~* Females of childbearing potential not using specified contraception, subjects with malignant tumors with a short life expectancy, subjects with known severe reactions to drugs and subjects with bilateral renal artery stenosis will be excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Nutraceutical for Endometriosis Pain Relief

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed endometriosis and/or Positive NMR~* 18-49y~* Mean pain score \>6 on the assessment of pelvic pain (Visual analogue scale)~* Not eligible for surgery in the coming 3 months or had surgery \>3 months before inclusion in the study~* \>3 months intake of continue oral contraception (Oestrogen/Progesterone) before inclusion or no intake of oral contraception due to contraindication~* Has given voluntary, written, informed consent to participate in the study.~Exclusion Criteria:~* Planned surgery during study~* \<3 month intake of continue oral contraception (Oestrogen/Progesterone) before inclusion~* Chronic inflammatory disease (Chron's disease, Rheumatism,..)~* Pregnancy~* Bariatric surgery~* Malabsorption issues~* Allergy or hypersensitivity to the study product:~* Fish and products thereof: fish oil~* Soybeans and products thereof~* Alcohol or substance abuse~* Start of gonadorelin analogue (ex. Busereline, Gosereline, triptoreline) therapy in the past 6 months~* Intake of other food supplements, including omega 3 and omega 6~* Any other condition which in the investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Specialized nutraceutical (Type: ACTIVE_COMPARATOR): Specialized nutraceutical formulated in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.
- Placebo (Type: PLACEBO_COMPARATOR): Identical placebo formulated without active ingredients in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Peri-Operative Magnesium Infusion to Prevent Atrial Fibrillation Evaluated.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective cardiac surgery (valve surgery and/or CABG)~* 18 years and above~* Mentally competent~Exclusion Criteria:~* History of atrial fibrillation (AF) or atrial flutter.~* Concomitant rhythm associated procedures (MAZE (surgical ablation)/PVI (pulmonary vein isolation)).~* Pre-existing severe renal impairment (eGFR\<30 ml/min).~* Pre-existing 3rd degree heart block without pacemaker presence.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Magnesium Sulfate (Type: ACTIVE_COMPARATOR): Magnesium sulfate is the active compound and will be administered to achieve plasma serum level of magnesium between 1.5 and 2.0 mmol/L according to the study protocol.
- Ringers Lactate (Type: PLACEBO_COMPARATOR): Ringers Lactate is the comparator/placebo and will be administered according to the study protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Relaxation and Intensified Patient Surgery Education in Patients Undergoing Colorectal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* referral for colorectal surgery~* preoperative anxiety at least 4/10 points on a numeric rating scale~* physical and mental capability to participant~* written informed consent~Exclusion Criteria:~* Emergency surgery~* known malignoma~* severe comorbidity~* severe psychological disorders~* immunosuppression~* coagulation disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual care (Type: NO_INTERVENTION): Does not receive a specific study intervention
- preoperative relaxation program (Type: EXPERIMENTAL): preoperative relaxation program
- preoperative surgery education (Type: EXPERIMENTAL): single education unit to understand the complete surgical procedures
- preop relaxation and surgery education (Type: EXPERIMENTAL): preoperative relaxation program AND single education unit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* Undergoing distal or midshaft osteotomy for bunion correction, 1st MTP Fusion, or cheilectomy~Exclusion Criteria:~* Age less than 18~* Unable to read/write English~* Dementia, history of dementia, or other significant mental impairment that would, in the opinion of the investigator, impede patient self-reporting~* Weight \<70 kg~* Allergy to local anesthetics~* History of long-acting opioid use or opioid tolerance (any patient receiving at least 30 mg of oxycodone or equivalent per day (e.g., 6 tabs of Percocet 5/325 mg) regularly for approximately 7 days or more OR who require increased analgesic doses for a period long enough to develop tolerance to the effects of the opioid including analgesia and sedation)~* Any history of opioid misuse, illicit or prescription~* Prior MTP joint correction on the surgical limb~* Midfoot and hindfoot procedures performed concurrently, on the same day~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regional Block (Type: ACTIVE_COMPARATOR): Group A patients will receive only a pre-operative adductor canal block with 10 mL 0.5% ropivacaine plus a popliteal block with 30 mL 0.5% ropivacaine (total block 40 mL/200 mg).
- Regional Block Plus Exparel (Type: EXPERIMENTAL): Group B patients will receive the standard of care pre-operative adductor and popliteal block as described (40 mL/200 mg of 0.5% ropivacaine) in addition to a postoperative pericapsular injection of Exparel using 106 mg (8 mL, equivalent to 120 mg bupivacaine HCl), per the same total dose as provided in manufacturer recommendations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing Alternative Approaches for Blood Pressure Control: A3BC Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are at least 21 years old, and~* Have Stage 1 high blood pressure. (Defined as a systolic blood pressure between 140 mm Hg and 159 mm Hg (the top blood pressure number) and/or a diastolic blood pressure between 90 mm Hg and 99 mm Hg (the bottom blood pressure number) in the prior 6 months.)~Exclusion Criteria:~* Take drugs to control blood pressure.~* Have a history of left ventricular hypertrophy.~* Have a history of cardiovascular disease such as stroke, mini-strokes, heart attack, unstable angina, bypass surgery, stents, angioplasty, abnormal heart rhythms, heart failure, or peripheral artery disease.~* Have diabetes.~* Have a history of poor kidney function.~* Have an upper arm circumference greater than 17 inches.~* Are currently participating in a formal exercise or weight loss program.~* Plan to participate in a formal exercise or weight loss program in the next 6 months.~* Are pregnant or plan to become pregnant in the next 6 months.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Device Guided Breathing/Combination Therapy (Type: ACTIVE_COMPARATOR): Participants will first do device guided breathing for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
- Isometric Hand Grip/Combination Therapy (Type: ACTIVE_COMPARATOR): Participants will first do isometric hand grip exercises for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients 18 years of age or older.~* Confirmed and measurable metastatic melanoma with the BRAFV600 mutation.~* Patients with at least one metastatic melanoma lesion accessible. for biopsy prior to vemurafenib treatment if no archived tissue is available.~* Meet the requirements for HD IL-2 therapy per institutional guidelines.~* Meet the requirements for vemurafenib therapy per institutional guidelines.~* Patient must be willing to provide written Informed Consent and participate in study procedures as described in the 12PLK01. Patients consented for 12PLK01 will also be asked to participate in the 10PLK13 PROCLAIM (Proleukin®) registry study.~Exclusion Criteria:~* A patient will not be considered eligible for study participation if any of the following exclusion criteria are met:~* Prior therapy of metastatic disease with any of the following: IL-2, Ipilimumab, or other highly selective BRAF, MEK, NRAS, cMET inhibitors (e.g. GSK2118436 or GSK1120212) and TKIs.~  * Exception: with a 6 week washout the following are allowed:~    * Adjuvant Ipilimumab,~   * Anti PD-1, Anti PD L-1~* Exclusion for Cohort 1 only: vemurafenib treatment \>7 weeks.~* Exclusion for Cohort 2 only: vemurafenib treatment \<7 weeks. (eligible for Cohort 1) or \>18 weeks.~* QTc interval of \>500ms.~* Patients with known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) or other infectious hepatitis.~* Pregnant, nursing or planning to become pregnant.~* Untreated brain metastases. (Brain metastases that have been treated, which no longer require corticosteroid therapy and are without progression by MRI assessment at least 6 weeks after definitive therapy are acceptable.)~* Received investigational drug within 30 days prior to study dosing. Patients may participate in non-interventional or observational clinical study (ies)~* Concomitant disease or condition that would interfere with the conduct of the study or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: OTHER): Patients who have received less than 7 weeks vemurafenib dosing prior to treatment with HD IL-2
- Cohort 2 (Type: OTHER): Patients who have receive \>7 weeks to 18 weeks vemurafenib dosing prior to treatment with HD IL-2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Range of Motion Following Intraoperative Coban Dressing Application in Hand Burns

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Less than 15% burn, burn requires skin graft to dorsum of hand, burn involves at least 2 metacarpophalangeal joints~* 18 and older~Exclusion Criteria:~* Latex allergy~* Documented diagnoses of mental illness that interferes with patients ability to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): Application of Coban dressing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fluorescence Targeted Pelvic Lymph Node Mapping

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is willing and able to give informed consent for participation in the study.~* Male or Female, aged 18 years or above.~* Participant is undergoing elective curative surgery for rectal adenocarcinoma~* Participant is willing and able to comply with study requirements~Exclusion Criteria:~* Participant has history of or known allergy to indocyanine green~* Participant has history of or known allergy to iodides~* Participant suffers from hyperthyroidism or has a benign thyroid tumour~* Participant has renal failure~* Female participant currently pregnant, planning pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tumour injection of ICG (Type: EXPERIMENTAL): Indocyanine green injection into tumour before or during surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient successfully completed the Phase 1b/2a study with WVE-120102, WVE-HDSNP2-001.~Exclusion Criteria:~1. Received an investigational drug other than WVE-120102, including an investigational oligonucleotide, within the past 1 year or 5 half-lives of the drug, whichever is longer.~2. Inability to undergo brain MRI (with or without sedation).~3. Clinically significant medical finding on the physical examination other than HD that, in the judgment of the Investigator, will make the patient unsuitable for participation in and/or completion of the study procedures.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WVE-120102 (Dose A) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than 12 hrs of age and less than 10 days chronologic age~* 501-1000 gm~* Intubated and mechanically ventilated before 12 hrs~* Indwelling vascular catheter~* Infants 751-100 gm must be receiving FiO2 greater than 0.30 and have received at least 1 dose of surfactant at randomization~* Parental consent~Exclusion Criteria:~* Major congenital anomaly~* Symptomatic non-bacterial infection~* Permanent neuromuscular conditions that affect respiration~* Terminal illness (defined as pH values less than 6.8 for more than 2 hours or persistent bradycardia associated with hypoxia for more than 2 hours)~* Use of postnatal corticosteroids

- Gender: ALL
- Minimum Age: 5 Minutes
- Maximum Age: 10 Days
- Healthy Volunteers: f

Study Arms:
- Minimal ventilation with Dexamethasone (Type: EXPERIMENTAL): Minimal ventilator support strategy (permissive hypercapnia) and early stress dose dexamethasone therapy
- Minimal Ventilation without Dexamethasone (Type: EXPERIMENTAL): Minimal ventilator support strategy (permissive hypercapnia) and no dexamethasone therapy
- Routine ventilation with Dexamethasone (Type: ACTIVE_COMPARATOR): None
- Routine ventilation without Dexamethasone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Timing of Insulin Before Meals Everyday

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetic participants, History of insulin dependance for at least one year, A1C 7%-9%, normal CBC, Chemistry Profile,be sufficiently stable.~Exclusion Criteria:~* pregnant women, children, prisoners, mentally ill individuals, patients currently utilizing continuous glucose monitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Study Arm A (Type: PLACEBO_COMPARATOR): Study Arm A will be the primary control arm.
- Study Arm B (Type: EXPERIMENTAL): Study Arm B will serve as the intervention arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~The primary selection criteria include women and men between the ages of 18 and 65 who:~1. Meet DSM-IV criteria for opiate dependence,~2. Maintain a stable dose of methadone for two weeks prior to recruitment and:~   * fail to achieve take-home status for methadone dosing during at least the first four months of methadone treatment,~  * test positive on at least two toxicology screens for illicit drugs during the month prior to recruitment~  * have never achieved two consecutive toxicology screens free of illicit substances since entering the current treatment episode.~3. Meet study criteria for chronic stress:~   * unemployment criteria, and~  * affective disorder criteria.~Exclusion Criteria:~1. Patients with significantly unstable or uncontrolled medical illness which may interfere with participation in treatment (e.g., patients likely to require hospitalization during the study period).~2. Patients with a psychotic or organic mental disorder according to DSM-IV criteria.~3. Patients receiving medication affecting methadone metabolism (e.g. rifampin).~4. Patients with uncontrolled bipolar disorder as evidenced by meeting current criteria for mania or hypomania or meeting criteria for rapid cycling in the last year (as indicated by structured questioning of all patients meeting criteria for bipolar disorder).~5. Patients unable to complete the informed consent or unable to understand study procedures in the informed consent process.~6. Pregnancy or current alcohol use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- DCS-augmented CBT-IC (Type: EXPERIMENTAL): D-cycloserine-augmented CBT-IC
- Placebo-augmented CBT-IC (Type: PLACEBO_COMPARATOR): Placebo-augmented CBT-IC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues